Related references
Note: Only part of the references are listed.Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
Karthik Suresh et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
The Current Status of Immunotherapies in Esophagogastric Cancer
Geoffrey Y. Ku
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
Biagio Ricciuti et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease
Osamu Kanai et al.
THORACIC CANCER (2018)
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
Karthik Suresh et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Characteristics, incidence, and risk factors of immune checkpoint inhibitor related pneumonitis in patients with non-small cell lung cancer
Jun Yeun Cho et al.
LUNG CANCER (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas
Yi Wang et al.
ANNALS OF HEMATOLOGY (2018)
Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Hazem I. Assi et al.
CANCER (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials
B. El Osta et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions
M. B. Atkins et al.
ANNALS OF ONCOLOGY (2017)
Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis
Sandro Pasquali et al.
CANCER TREATMENT REVIEWS (2017)
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
Claire F. Friedman et al.
JAMA ONCOLOGY (2016)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi et al.
LANCET ONCOLOGY (2015)
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
Masayuki Takeda et al.
LUNG CANCER (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Interstitial lung disease in Japanese patients with lung cancer - A cohort and nested case-control study
Shoji Kudoh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)